Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gel-One (also known as Gel-200) is a cross-linked hyaluronan (hyaluronic acid) viscoelastic hydrogel developed by Seikagaku Corporation and marketed by Zimmer Biomet. It is indicated for the treatment of pain in patients with osteoarthritis of the knee who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics. The product consists of highly purified sodium hyaluronate extracted from avian sources (chicken combs), which is cross-linked using cinnamic acid dimers to increase its viscoelastic properties and residence time in the joint. As a viscosupplement, it acts by providing mechanical lubrication and shock absorption within the synovial space, mimicking the properties of healthy synovial fluid. It is administered as a single 3 mL intra-articular injection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on crosslinked hyaluronan gel.